Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma
Rattachement africain : it, ch, de, jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Treatment duration with checkpoint inhibitors must be optimized to prevent unjustified toxicity, but evidence for the management of cutaneous squamous cell carcinoma is lacking. A retrospective study was performed to evaluate the survival of patients with cutaneous squamous cell carcinoma (CSCC) who discontinued cemiplimab due to different causes and without progression. Among 95 patients with CSCC who received cemiplimab, 22 (23%) patients discontinued immunotherapy due to causes other than progression, such as comorbidities, toxicity, complete response or lack of compliance (group that discontinued before censoring [DBC]), then 73 patients had standard treatment scheduled (STS). The overall survival was 25.2 months (95% CI: 8.9–29.4) in STS group and 28.3 months (95% CI: 12.7–28.3) in the DBC group; deaths for all causes were 11/22 (50%) in the DBC group and 34/73 (46.6%) in the STS group (p=0.32). 10/22 (45.4%) subjects died due to CSCC in the DBC after discontinuation and 34/73 (46.6%) in the STS group, and the difference between groups was not significant (p=0.230). Duration of treatment was significantly lower in subjects with stable disease vs those with complete or partial response (16.9, 30.6 and 34.9 months, respectively; p=0.004). Among the 22 STS patients, 12 received cemiplimab for less than 12 months (10 [83%] died) and 10 for at least 12 months (1 [10%] died). This observational study suggests that immune checkpoint inhibitor treatment in patients with advanced CSCC should be discontinued at least after complete response or after 12 months despite lack of response or progression.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma
- Date Crossref
- 05/03/2024
- Éditeur
- Research Square Platform LLC
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" pays non établi dans la noticeÉtablissement de santé
-
University of Naples Federico II pays non établi dans la noticeUniversité ou école supérieure
-
Roche (Switzerland) pays non établi dans la noticeEntreprise
-
Novartis (Switzerland) pays non établi dans la noticeEntreprise
-
Daiichi Sankyo (Germany) pays non établi dans la noticeEntreprise
-
Pierre Fabre (Germany) pays non établi dans la noticeEntreprise
-
MSD K.K. (Japan) pays non établi dans la noticeEntreprise
-
Merck Serono S.A. (Switzerland) pays non établi dans la noticeEntreprise
-
Istituto Nazionale Tumori – IRCCS – Fondazione ‘G. Pascale’ pays non établi dans la noticeInstitution
-
AstraZeneca pays non établi dans la noticeInstitution
-
Myers Squibb pays non établi dans la noticeInstitution
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Naples Federico II et Roche (Switzerland), avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.